Busulfan-Fludarabine Versus Busulfan-Cyclophosphamide for Allogeneic Transplant in Acute Myeloid Leukemia: Long Term Analysis of GITMO AML-R2 Trial

Investigators reported the long-term results of a randomized trial, comparing 1:1 the combination of busulfan and cyclophosphamide and the combination of busulfan and fludarabine as a conditioning regimen in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.